Women with breast cancer had higher than normal levels of severe anxiety, depression, distress, and insomnia at the peak of the COVID-19 outbreak in the Hubei Province in China, study findings indicate.
Combining pyrotinib instead of lapatinib with capecitabine is associated with significantly improved progression-free survival in patients who have received prior treatment for HER2-positive metastatic breast cancer, show phase 3 trial data.
Individuals who present with metastatic breast cancer do not experience improvement in overall survival or other outcomes with early locoregional therapy for an intact primary tumor, according to ECOG-ACRIN 2108 trial findings.
Findings from the proof-of-principle Olaparib Expanded study indicate that patients with stage IV breast cancer and germline PALB2 or somatic BRCA1/2 mutations may benefit from olaparib treatment.
Adjuvant treatment with trastuzumab emtansine does not improve outcome or reduce toxicity relative to that with a taxane plus trastuzumab in patients with HER2-positive early breast cancer, results of the phase 3 KAITLIN study show.